1 week Ago By Defense World Staff
Prudential Financial Inc. lowered its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 5.
3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,737 shares of the company’s stock after selling 1,150 shares during the quarter. Prudential Financial Inc.
owned approximately 0.07% of Fulgent Genetics worth $383,000 as of its most recent SEC filing. Other hedge funds also recently made changes to their positions in the company.
GAMMA Investing LLC lifted its stake in shares of Fulgent Genetics by 45.5% in the 4th quarter. GAMMA Investing LLC now owns 2,133 shares of the company’s stock valued at $39,000 after acquiring an additional 667 shares during the last quarter.
KLP Kapitalforvaltning AS acquired a new position in Fulgent Genetics in the 4th quarter worth about $57,000. R Squared Ltd bought a new position in Fulgent Genetics in the fourth quarter valued at about $74,000. Amundi raised its position in Fulgent Genetics by 143.
7% in the fourth quarter. Amundi now owns 8,816 shares of the company’s stock valued at $166,000 after purchasing an additional 5,199 shares during the last quarter. Finally, Wealthspire Advisors LLC acquired a new stake in shares of Fulgent Genetics during the fourth quarter valued at about $186,000.
48.06% of the stock is currently owned by institutional investors and hedge funds. Fulgent Genetics Price PerformanceShares of FLGT stock opened at $17.
66 on Thursday. The stock has a market capitalization of $545.09 million, a PE ratio of -3.
20 and a beta of 1.36. The business’s 50 day simple moving average is $16.
83 and its 200 day simple moving average is $18.34. Fulgent Genetics, Inc.
has a one year low of $14.57 and a one year high of $25.11.
Insider ActivityIn other Fulgent Genetics news, CFO Paul Kim purchased 100,000 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were purchased at an average cost of $15.96 per share, with a total value of $1,596,000.
00. Following the completion of the purchase, the chief financial officer now owns 348,282 shares in the company, valued at $5,558,580.72.
This represents a 40.28 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Insiders own 31.76% of the company’s stock. Analyst Upgrades and DowngradesA number of research analysts recently issued reports on the stock.
Piper Sandler dropped their price objective on shares of Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th.
StockNews.com raised shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 5th.Read Our Latest Stock Report on Fulgent GeneticsAbout Fulgent Genetics (Free Report)Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.Featured StoriesFive stocks we like better than Fulgent GeneticsWhich Wall Street Analysts are the Most Accurate?Quantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreTransportation Stocks InvestingAre Tariffs Threatening Disney’s Comeback Story?How to Most Effectively Use the MarketBeat Earnings ScreenerIs Alphabet a Generational Buying Opportunity at These Levels?.
